Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

Metabolic

Approved

Semaglutide is a GLP-1 receptor agonist peptide that has become one of the most significant metabolic therapeutics in recent history. Originally approved for type 2 diabetes, it has demonstrated unprecedented weight loss efficacy and is now being studied for cardiovascular protection, NASH, and Alzheimer's disease.

Regulatory & Approval Status

FDA Approved

Semaglutide is FDA-approved for type 2 diabetes and chronic weight management under brand names including Ozempic, Rybelsus, and Wegovy, with recent approvals for higher-dose formulations.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.